Mechanistic studies showed that CSRP2 could inhibit the phosphorylation of p130Cas and activation of Rac1, which then activated the Hippo pathway and inhibited PAK-LIMK-cortactin and ERK signaling pathways, thereby impeding EMT and metastasis of CRC. This evidence concerns the gene LIMK1 and colorectal carcinoma.